693 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
AMGN Amgen Inc. $200.81 $129.98B N/A
Article Searches
Pfizer (PFE) to Report Q1 Earnings: Will It Beat Estimates? http://www.zacks.com/stock/news/398971/pfizer-pfe-to-report-q1-earnings-will-it-beat-estimates?cid=CS-ZC-FT-398971 Apr 24, 2019 - While Pfizer's (PFE) key drugs like Ibrance and Xeljanz are likely to drive Q1 sales, genericization of key drugs and weak sales in the EH segment will hurt.
Novartis (NVS) Q1 Earnings Beat Estimates, Revenues Up Y/Y http://www.zacks.com/stock/news/394696/novartis-nvs-q1-earnings-beat-estimates-revenues-up-y-y?cid=CS-ZC-FT-394696 Apr 24, 2019 - Novartis (NVS) beats on Q1 earnings, sales marginally miss estimates.
Analysts Estimate Amgen (AMGN) to Report a Decline in Earnings: What to Look Out for http://www.zacks.com/stock/news/393228/analysts-estimate-amgen-amgn-to-report-a-decline-in-earnings-what-to-look-out-for?cid=CS-ZC-FT-393228 Apr 23, 2019 - Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top Analyst Reports for Bank of America, Amgen & NextEra Energy http://www.zacks.com/research-daily/379778/top-analyst-reports-for-bank-of-america-amgen-nextera-energy?cid=CS-ZC-FT-379778 Apr 12, 2019 - Top Analyst Reports for Bank of America, Amgen & NextEra Energy
Merck's Keytruda Gets FDA Nod for Expanded Lung Cancer Group http://www.zacks.com/stock/news/379812/mercks-keytruda-gets-fda-nod-for-expanded-lung-cancer-group?cid=CS-ZC-FT-379812 Apr 12, 2019 - Merck (MRK) gets FDA approval to include overall survival data from the KEYNOTE-042 study on Keytruda's label.
Biotech Stock Roundup: AMGN's Evenity Earns FDA Approval, Deal Wins & More http://www.zacks.com/stock/news/376834/biotech-stock-roundup-amgns-evenity-earns-fda-approval-deal-wins-more?cid=CS-ZC-FT-376834 Apr 10, 2019 - Key highlights of the past week are new drug approvals, collaborations and pipeline updates.
Why Amgen (AMGN) is Poised to Beat Earnings Estimates Again http://www.zacks.com/stock/news/371457/why-amgen-amgn-is-poised-to-beat-earnings-estimates-again?cid=CS-ZC-FT-371457 Apr 05, 2019 - Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Pfizer's New Lung Cancer Drug Vizimpro Gets EU Approval http://www.zacks.com/stock/news/370846/pfizers-new-lung-cancer-drug-vizimpro-gets-eu-approval?cid=CS-ZC-FT-370846 Apr 04, 2019 - Pfizer's (PFE) new lung cancer medicine, Vizimpro (dacomitinib) gets approval in EU after being approved in the United States last September.
Novartis Resubmits BLA to FDA for Biosimilar of Neulasta http://www.zacks.com/stock/news/370752/novartis-resubmits-bla-to-fda-for-biosimilar-of-neulasta?cid=CS-ZC-FT-370752 Apr 04, 2019 - Novartis' (NVS) generic arm Sandoz resubmits its BLA for the proposed biosimilar of Neulasta.
Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL http://www.zacks.com/stock/news/365652/biotech-stock-roundup-biib-cnat-crash-on-study-failures-lxrx-gets-crl?cid=CS-ZC-FT-365652 Mar 27, 2019 - Key highlights of the past week are multiple study failures and other pipeline updates.

Pages: 123456789...70

<<<Page 4>